PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDeferoxamine
Deferoxamine
Deferoxamine, Desferal (deferoxamine) is a small molecule pharmaceutical. Deferoxamine was first approved as Desferal on 1982-01-01. It is used to treat bone diseases, corneal diseases, and hemochromatosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Deferoxamine, Desferal (discontinued: Deferoxamine, Desferal)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferoxamine mesylate
Tradename
Company
Number
Date
Products
DESFERALNovartisN-016267 RX1982-01-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
deferoxamineANDA2025-03-20
deferoxamine mesylateANDA2025-09-17
desferalNew Drug Application2025-06-17
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V03: All other therapeutic products
V03A: All other therapeutic products
V03AC: Iron chelating agents
V03AC01: Deferoxamine
HCPCS
Code
Description
J0895
Injection, deferoxamine mesylate, 500 mg
Clinical
Clinical Trials
83 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron overloadD01919011553525
ThalassemiaD013789EFO_1001996D5621145625
Beta-thalassemiaD017086Orphanet_848D56.11955421
Sickle cell anemiaD000755EFO_0000697D5716139
HemochromatosisD006432EFO_1000642E83.1143219
HemosiderosisD00648643219
AnemiaD000740EFO_0004272D64.93216
Heart diseasesD006331EFO_0003777I51.91124
Covid-19D000086382U07.111113
CardiomyopathiesD009202EFO_0000318I4211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral hemorrhageD0025432416
StrokeD020521EFO_0000712I63.91124
HemorrhageD006470MP_0001914R582214
Intracranial hemorrhagesD020300EFO_0000551I621213
CarcinomaD002277C80.0112
Oxidative stressD018384EFO_1001905111
Renal cell carcinomaD002292EFO_000037611
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80515
Myelodysplastic syndromesD009190D46224
PreleukemiaD011289123
Hematologic diseasesD006402EFO_0005803D75.9213
Subarachnoid hemorrhageD013345EFO_0000713I60223
SyndromeD013577112
UlcerD014456MPATH_579122
Ischemic strokeD000083242112
IschemiaD007511EFO_0000556112
Acute kidney injuryD058186N1722
Show 23 more
Indications Phases 1
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDeferoxamine
INNdeferoxamine
Description
Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Identifiers
PDB
CAS-ID70-51-9
RxCUI
ChEMBL IDCHEMBL556
ChEBI ID4356
PubChem CID2973
DrugBankDB00746
UNII IDJ06Y7MXW4D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Deferoxamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,335 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,734 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use